In the current environment, it is possible for women with late-stage breast cancer to do very well for long periods of time. There are so many options, both new and old, to treat metastatic breast cancer.
Metastatic, another word for late-stage breast cancer, means the disease has spread beyond the breast to other parts of the body.Read More
New Developments for Advanced Breast Cancer
HER2-positive breast cancerFor women with HER2-positive breast cancer, meaning they have high levels of a protein called HER2 on the surface of their cancer cells, targeted treatments are available. The drugs trastuzumab (Herceptin) and pertuzumab (Perjeta) have transformed the outlook for some women with late-stage breast cancers. These therapies, which are often combined with chemo, are very effective at controlling breast cancer once it has spread.
Exciting new research has also indicated that women with metastatic HER2-“low” breast cancer may have new options as well. In the past, doctors divided patients into two categories based on HER2 expression: HER2 positive tumors and HER2 negative tumors. Recently, however, researchers have looked to further expand this definition to include patients who have a minimal amount of HER2 expression but do not meet the classic definition for HER2-positive tumors. This means there could be more treatment options for women who fall in this HER2-“low” category.
Triple-negative breast cancer
Another big advancement has come in the treatment of triple-negative breast cancer. This has historically been one of the most aggressive and hardest to treat forms of the disease, because it lacks any of the main drivers of breast cancer — the estrogen receptor, the progesterone receptor, and the HER2 receptor — and it doesn’t respond to treatments that target these receptors.
Now, in addition to chemotherapy, immunotherapy has been approved to treat triple-negative breast cancer. In studies, this new therapy has been shown to extend the lives of women with this type of cancer.
Recently, a new antibody drug conjugate showed promise in extending life and progression-free survival in some women with triple negative breast cancer as well.
Hormone-receptor-positive breast cancer
For postmenopausal women with hormone-receptor-positive and HER2-negative breast cancers, a newer class of drugs called CDK4/6 inhibitors are available. These drugs have been shown to improve survival in some women with metastatic cancer.
Estrogen receptor-positive means that this type of cancer needs the hormone estrogen to grow. These CD4/CD6 drugs work to decrease the amount of estrogen that can be taken into a cancer cell, with the goal of slowing the rate at which that cancer cell can expand.